Jump to content

Eisai (company): Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Aftov (talk | contribs)
27 edits
No edit summary
infobox
 
(38 intermediate revisions by 23 users not shown)
Line 1: Line 1:
{{short description|Japanese pharmaceutical company}}
{{Short description|Japanese pharmaceutical company}}
{{Multiple issues|
⚫
{{Use mdy dates|date=February 2015}}
{{More citations needed|date=January 2018}}
{{More citations needed|date=January 2018}}
{{Expand Japanese|エーザイ|date=March 2020}}
{{Expand Japanese|エーザイ|date=March 2020}}
}}
⚫
{{Infobox company
⚫
{{Use mdy dates|date=February 2015}}
⚫
|name = Eisai Co., Ltd.

⚫
|native_name = エーザイ株式会社
⚫
{{Infobox company
⚫
|native_name_lang = ja
⚫
| name = Eisai Co., Ltd.
⚫
|romanized_name = Ēzai kabushiki gaisha
⚫
| native_name = エーザイ株式会社
⚫
|logo = Eisai logo.svg
⚫
| native_name_lang = ja
⚫
|logo_size = 200px
⚫
| romanized_name = Ēzai kabushiki gaisha
⚫
|type = [[Public company|Public]] [[Kabushiki gaisha|KK]]
⚫
| logo = Eisai logo.svg
⚫
|traded_as = {{TYO|4523}}<br>[[Topix|TOPIX Large 70 Component]]<br>[[Topix|TOPIX 100 Component]]<br>[[Nikkei 225|Nikkei 225 Component]]
⚫
| logo_size = 200px
⚫
|founder = Toyoji Naito
| image = Eisai Head Office.jpg
⚫
|foundation = {{Start date and age|1941|12|06}}
⚫
| type = [[Public company|Public]] [[Kabushiki gaisha|KK]]
⚫
|location = 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
⚫
| traded_as = {{TYO|4523}}<br>[[Topix|TOPIX Large 70 Component]]<br>[[Topix|TOPIX 100 Component]]<br>[[Nikkei 225|Nikkei 225 Component]]
⚫
|key_people = Haruo Naito<br><small>([[President (corporate title)|President]] and [[CEO]])</small>
⚫
| founder = Toyoji Naito
⚫
|industry = [[Pharmaceutical company|Pharmaceuticals]]
⚫
| foundation = {{Start date and age|1941|12|06}}
⚫
|products = {{unbulleted list|
⚫
| location = 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
⚫
| key_people = Haruo Naito<br><small>([[President (corporate title)|President]] and [[CEO]])</small>
⚫
| industry = [[Pharmaceutical company|Pharmaceuticals]]
⚫
| products = {{unbulleted list|[[Leqembi |Lecanemab]] |
[[Lenvatinib|Lenvema]]|
[[Lenvatinib|Lenvema]]|
[[Eribulin|Halaven]]|
[[Eribulin|Halaven]]|
[[Donepezil|Aricept]]|[[Rabeprazole|Pariet]]|[[Banzel]]|[[Zonisamide#History|Zonegran]]|[[Perampanel|Fycompa]]|[[Eslicarbazepine acetate|Zebinix]]}}
[[Donepezil|Aricept]]|[[Rabeprazole|Pariet]]|[[Banzel]]|[[Zonisamide#History|Zonegran]]|[[Perampanel|Fycompa]]|[[Eslicarbazepine acetate|Zebinix]]}}
|revenue = {{increase}} [[US dollar|US$]] 5.82 billion ([[Fiscal year|FY]] 2013)<br><small>[[Japanese yen|JPY]] 600.4 billion (FY 2013)</small>
| revenue = {{Increase}} [[Japanese yen|¥]] 741.8 billion (2023)<ref name=EisaiRep23 />
| operating_income = {{Increase}} [[Japanese yen|¥]] 53.4 billion (2023)<ref name=EisaiRep23 />
|net_income = {{increase}} US$ 320 million (FY 2013)<br><small>JPY 33 billion (FY 2013)</small>
| net_income = {{Increase}} [[Japanese yen|¥]] 43.8 billion (2023)<ref name=EisaiRep23 />
|num_employees = 10,419 (consolidated, as of March 31, 2014)
| assets = {{Increase}} [[Japanese yen|¥]] 743.9 billion (2023)<ref name=EisaiRep23 />
⚫
|homepage = {{Official website|http://www.eisai.com/index.html}}
| equity = {{Increase}} [[Japanese yen|¥]] 430.2 billion (2023)<ref name=EisaiRep23 />
|footnotes = {{citation needed|date=February 2020}}
| owner = [[The Master Trust Bank of Japan]] <small>(11.78%)</small><br />[[Japan Trustee Services Bank]] <small>(10.99%)</small><br />[[Nippon Life]] <small>(4.29%)<ref name=EisaiRep19 /></small>
| num_employees = {{Increase}} 10,000 (2023)<ref name=EisaiRep23 />
⚫
| homepage = {{Official website|http://www.eisai.com}}
| footnotes = <ref name=EisaiRep19>{{cite web|title=Eisai Financial Summary 2019|url=http://fs.magicalir.net/tdnet/2019/4523/20190513422653.pdf|access-date=21 December 2020}}</ref>
<ref name=EisaiRep23>{{cite web|title=Eisai Financial Summary 2023|url=https://www.eisai.com/ir/library/settlement/pdf/e2024Q4_51.pdf|access-date=2 July 2024}}</ref>
}}
}}


{{nihongo|'''Eisai Co., Ltd.'''|エーザイ株式会社|Ēzai Kabushiki-gaisha|lead=yes}} is a Japanese [[pharmaceutical company]] headquartered in [[Tokyo]], Japan. It has some 10,000 employees, among them about 1,500 in research. '''Eisai''' is listed on the [[Tokyo Stock Exchange]] and is a member of the [[Topix|Topix 100]] and [[Nikkei 225]] [[stock index|stock indices]].<ref>{{cite web |url=http://indexes.nikkei.co.jp/en/nkave/index/component?idx=nk225#09 |title=Components:Nikkei Stock Average |publisher=[[Nihon Keizai Shimbun]] |accessdate=February 9, 2015}}</ref>
{{nihongo|'''Eisai Co., Ltd.'''|エーザイ株式会社|Ēzai Kabushiki-gaisha|lead=yes}} is a Japanese [[pharmaceutical company]] headquartered in [[Tokyo]], Japan. It has some 10,000 employees, among them about 1,500 in research. '''Eisai''' is listed on the [[Tokyo Stock Exchange]] and is a member of the [[Topix|Topix 100]] and [[Nikkei 225]] [[stock index|stock indices]].<ref>{{cite web |url=http://indexes.nikkei.co.jp/en/nkave/index/component?idx=nk225#09 |title=Components:Nikkei Stock Average |publisher=[[Nihon Keizai Shimbun]] |access-date=February 9, 2015}}</ref>


==History ==
==History ==
Nihon Eisai Co. Ltd. was established in 1941.<ref>https://www.eisai.com/company/profile/history/index.html</ref> In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.<ref>{{cite encyclopedia |first=Claudia |last=Winograd |editor-last=Colditz |editor-first=Graham A. |title=Eisai (Japan) | encyclopedia=Encyclopedia of Cancer and Society |date=October 16, 2007 |publisher=[[Sage Publications]] |url=http://www.sageknowledge.org/view/cancer/n204.xml |doi=10.4135/9781412953979 |isbn=9781412949897 |accessdate=February 9, 2015 }}</ref> The American subsidiary of the company, Eisai Inc., was established in 1995.<ref>{{cite web |url=http://www.businesswire.com/news/home/20100618005322/en/Lonnel-Coats-Appointed-President-Chief-Executive-Officer#.VNik5S5vW4A |title=Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc. |publisher=[[Businesswire]] |accessdate=February 9, 2015}}</ref>
Nihon Eisai Co. Ltd. was established in 1941.<ref>{{cite web|url=https://www.eisai.com/company/profile/history/index.html|title = Eisai: The First 80 Years &#124; Eisai Co., Ltd}}</ref> In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.<ref>{{cite encyclopedia |first=Claudia |last=Winograd |editor-last=Colditz |editor-first=Graham A. |title=Eisai (Japan) |encyclopedia=Encyclopedia of Cancer and Society |date=October 16, 2007 |publisher=[[SAGE Publications]] |url=http://www.sageknowledge.org/view/cancer/n204.xml |doi=10.4135/9781412953979 |isbn=9781412949897 |access-date=February 9, 2015 |archive-date=February 9, 2015 |archive-url=https://web.archive.org/web/20150209165035/http://www.sageknowledge.org/view/cancer/n204.xml |url-status=dead }}</ref> The American subsidiary of the company, Eisai Inc., was established in 1995.<ref>{{cite press release |url=http://www.businesswire.com/news/home/20100618005322/en/Lonnel-Coats-Appointed-President-Chief-Executive-Officer#.VNik5S5vW4A |title=Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc. |publisher=[[Businesswire]] |access-date=February 9, 2015}}</ref>


On November 25, 1996, Eisai received [[Approved drug|approval]] from the United States [[Food and Drug Administration]] (USFDA) for Aricept ([[donepezil]]), a drug discovered in the company's labs and co-marketed with [[Pfizer]].<ref>https://www.newspapers.com/image/102245190/?terms=Aricept</ref>
On November 25, 1996, Eisai received [[Approved drug|approval]] from the United States [[Food and Drug Administration]] (USFDA) for Aricept ([[donepezil]]), a drug discovered in the company's labs and co-marketed with [[Pfizer]].<ref>{{cite web|url=https://www.newspapers.com/image/102245190/?terms=Aricept |title=27 Nov 1996, Page 11 - The Cincinnati Enquirer at |publisher=Newspapers.com |date=1996-11-27 |accessdate=2022-06-05}}</ref>


Three years later in 1999, the company received USFDA approval for Aciphex ([[rabeprazole]]), a drug co-marketed with [[Johnson & Johnson]].
Three years later in 1999, the company received USFDA approval for Aciphex ([[rabeprazole]]), a drug co-marketed with [[Johnson & Johnson]].


In September 2006, the company acquired four oncology products from [[Ligand Pharmaceuticals]].<ref>{{Cite web|url=https://www.biospace.com/article/eisai-inc-buys-4-cancer-drugs-from-ligand-pharmaceuticals-inc-for-205-million-/|title=Eisai Inc. Buys 4 Cancer Drugs From Ligand Pharmaceuticals Inc. For $205 Million|website=BioSpace|language=en-US|access-date=2020-02-21}}</ref>
In September 2006, the company acquired four oncology products from [[Ligand Pharmaceuticals]].<ref>{{cite web|url=https://www.biospace.com/article/eisai-inc-buys-4-cancer-drugs-from-ligand-pharmaceuticals-inc-for-205-million-/|title=Eisai Inc. Buys 4 Cancer Drugs From Ligand Pharmaceuticals Inc. For $205 Million|website=BioSpace|language=en-US|access-date=2020-02-21}}</ref>


In April 2007, Eisai acquired [[Exton, Pennsylvania]]-based Morphotek, a company developing [[Monoclonal antibody therapy|therapeutic monoclonal antibodies]] for the treatment of cancer, rheumatoid arthritis, and infectious diseases.
In April 2007, Eisai acquired [[Exton, Pennsylvania]]-based Morphotek, a company developing [[Monoclonal antibody therapy|therapeutic monoclonal antibodies]] for the treatment of cancer, rheumatoid arthritis, and infectious diseases.
Line 43: Line 52:
In December 2007, Eisai acquired [[MGI Pharma]], a company specializing in oncology, for US$3.9 billion.<ref>{{Cite news|url=https://www.reuters.com/article/us-mgi-pharma-eisai-idUSTKV00291420071210|title=Japan's Eisai to buy MGI Pharma for $3.9 bln|date=2007-12-10|work=Reuters|access-date=2019-11-20|language=en}}</ref> This event brought Dacogen ([[decitabine]]), Aloxi ([[palonosetron]]), Hexalen ([[altretamine]]) for ovarian cancer, and the Gliadel Wafer ([[carmustine]]) for brain tumors into the Eisai product portfolio.
In December 2007, Eisai acquired [[MGI Pharma]], a company specializing in oncology, for US$3.9 billion.<ref>{{Cite news|url=https://www.reuters.com/article/us-mgi-pharma-eisai-idUSTKV00291420071210|title=Japan's Eisai to buy MGI Pharma for $3.9 bln|date=2007-12-10|work=Reuters|access-date=2019-11-20|language=en}}</ref> This event brought Dacogen ([[decitabine]]), Aloxi ([[palonosetron]]), Hexalen ([[altretamine]]) for ovarian cancer, and the Gliadel Wafer ([[carmustine]]) for brain tumors into the Eisai product portfolio.


In 2009, Eisai received the Corporate Award from the [[National Organization for Rare Disorders]] (NORD) for the development of [[Banzel]].<ref>{{cite news |url=http://www.prnewswire.com/news-releases/nord-to-honor-rare-disease-pioneers-61818702.html |archiveurl=https://web.archive.org/web/20150209123421/http://www.prnewswire.com/news-releases/nord-to-honor-rare-disease-pioneers-61818702.html |archivedate=February 9, 2015 |title=NORD to Honor Rare Disease Pioneers |publisher=[[PR Newswire]] |date=May 11, 2009 |accessdate=February 9, 2015}}</ref>
In 2009, Eisai received the Corporate Award from the [[National Organization for Rare Disorders]] (NORD) for the development of Banzel ([[rufinamide]]).<ref>{{cite news |url=http://www.prnewswire.com/news-releases/nord-to-honor-rare-disease-pioneers-61818702.html |archive-url=https://web.archive.org/web/20150209123421/http://www.prnewswire.com/news-releases/nord-to-honor-rare-disease-pioneers-61818702.html |archive-date=February 9, 2015 |title=NORD to Honor Rare Disease Pioneers |publisher=[[PR Newswire]] |date=May 11, 2009 |access-date=February 9, 2015}}</ref>

In June 2023, the company suffered from a [[ransomware]] attack, causing a shutdown of some of its logistical systems.<ref>{{cite web | url=https://www.securityweek.com/pharmaceutical-giant-eisai-takes-systems-offline-following-ransomware-attack/ | title=Pharmaceutical Giant Eisai Takes Systems Offline Following Ransomware Attack | date=June 8, 2023 }}</ref>

[[Lecanemab]], branded as "Leqembi" was approved by the U.S. Food and Drug Administration (FDA) in January 2023 under an Accelerated Approval pathway.<ref>{{Cite web |last=Commissioner |first=Office of the |date=2023-01-06 |title=FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment |url=https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment |access-date=2024-07-02 |website=FDA |language=en}}</ref> The approval was converted into a traditional approval in July 2023.<ref>{{Cite web |last=Commissioner |first=Office of the |date=2023-07-07 |title=FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval |url=https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval |access-date=2024-07-02 |website=FDA |language=en}}</ref>


==Locations==
==Locations==
⚫
Eisai Co., Ltd. is based in [[Tokyo]], Japan, while its American subsidiary, Eisai Inc., is headquartered in [[Nutley, New Jersey]]. Eisai Inc. is led by Ivan Cheung as CEO.<ref>{{Cite news |last=Bell |first=Jacob |date=February 6, 2023 |title=Eisai gives first glimpse into Alzheimer's drug launch |work=BiopharmaDive |publisher=[[Informa]] |location=Washington, D.C. |url=https://www.biopharmadive.com/news/eisai-alzheimers-leqembi-launch-earnings/642067/ |access-date=February 11, 2023 |archive-url=https://web.archive.org/web/20230206223238/https://www.biopharmadive.com/news/eisai-alzheimers-leqembi-launch-earnings/642067/ |archive-date=February 6, 2023}}</ref> Eisai maintains [[medical research]] headquarters in Nutley as well as at locations in [[Japan]], the [[United Kingdom]], the Research Triangle in [[North Carolina]], and [[Massachusetts]] where the Eisai Research Institute and the Genetics Guided Dementia Discovery (G2D2) institute are based.<!--caroll2016 and genengnews2016 citations only support the Andover Institute--><ref name="carroll2016">{{Cite news|url=https://endpts.com/eisai-launches-research-division-in-massachusetts-aimed-at-alzheimers-io-and-autoimmune-diseases/|title=Eisai launches biotech division in Massachusetts aimed at Alzheimer's, I/O and autoimmune diseases|last=Carroll|first=John|date=15 September 2016|work=Endpoint News|access-date=4 November 2016}}</ref><ref name="genengnews2016">{{Cite news|title=Eisai Launches Facility to Advance Precision Medicine|last=<!--Staff, no byline-->|date=15 October 2016|work=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]]|department=News: Industry Watch|page=8|type=Paper}}</ref>
[[File:Eisai Head Office.jpg|thumb|Eisai head office in Tokyo]]
⚫
Eisai Co., Ltd. is based in [[Tokyo]], Japan, while its American subsidiary Eisai Inc. is headquartered in [[Woodcliff Lake, New Jersey]]. Eisai maintains [[medical research]] headquarters in Woodcliff Lake as well as at locations in [[Japan]], the [[United Kingdom]], the Research Triangle in [[North Carolina]], and [[Massachusetts]] where the Eisai Research Institute and the Genetics Guided Dementia Discovery (G2D2) institute are based.<!--caroll2016 and genengnews2016 citations only support the Andover Institute--><ref name="carroll2016">{{Cite news|url=https://endpts.com/eisai-launches-research-division-in-massachusetts-aimed-at-alzheimers-io-and-autoimmune-diseases/|title=Eisai launches biotech division in Massachusetts aimed at Alzheimer's, I/O and autoimmune diseases|last=Carroll|first=John|date=15 September 2016|work=Endpoint News|access-date=4 November 2016}}</ref><ref name="genengnews2016">{{Cite news|url=|title=Eisai Launches Facility to Advance Precision Medicine|last=<!--Staff, no byline-->|first=|date=15 October 2016|work=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]]|department=News: Industry Watch|page=8|type=Paper}}</ref>


The company has manufacturing sites in Japan, [[North Carolina|North Carolina (USA)]], [[Maryland|Maryland (USA)]], [[Bogor|Bogor (Indonesia)]], [[Suzhou|Suzhou (China)]], [[Tainan|Tainan (Taiwan)]], [[Visakhapatnam|Visakhapatnam (India)]] and [[Hatfield, Hertfordshire|Hatfield, Hertfordshire (UK)]]. Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.
The company has manufacturing sites in Japan, [[North Carolina|North Carolina (USA)]], [[Maryland|Maryland (USA)]], [[Bogor|Bogor (Indonesia)]], [[Suzhou|Suzhou (China)]], [[Tainan|Tainan (Taiwan)]], [[Visakhapatnam|Visakhapatnam (India)]] and [[Hatfield, Hertfordshire|Hatfield, Hertfordshire (UK)]]. Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.
Line 60: Line 72:
*Banzel/Inovelon ([[rufinamide]]) - Seizures related to [[Lennox-Gastaut syndrome|Lennox-Gastaut Syndrome]]
*Banzel/Inovelon ([[rufinamide]]) - Seizures related to [[Lennox-Gastaut syndrome|Lennox-Gastaut Syndrome]]
*Belviq ([[lorcaserin]]) - Obesity
*Belviq ([[lorcaserin]]) - Obesity
*Dayvigo ([[lemborexant]]) - Insomnia
*Fragmin ([[dalteparin]]) - Deep vein thrombosis and pulmonary embolism
*Fragmin ([[dalteparin]]) - Deep vein thrombosis and pulmonary embolism
*Fycompa ([[perampanel]]) - Partial-onset seizures
*Fycompa ([[perampanel]]) - Partial-onset seizures
⚫
*Gliadel Wafer ([[carmustine]]) - Treatment for Brain Tumors
*Halaven ([[eribulin]]) - Metastatic breast cancer
*Halaven ([[eribulin]]) - Metastatic breast cancer
*Iomeron ([[iomeprol]]) - Non-ionic contrast medium
*Iomeron ([[iomeprol]]) - Non-ionic contrast medium
⚫
*Lenvima ([[lenvatinib]]) - Thyroid Cancer or Kidney Cancer
*Leqembi ([[lecanemab]]) - [[Alzheimer's disease]]
*Methylcobal ([[methylcobalamin]]) - Peripheral neuropathy
*Methylcobal ([[methylcobalamin]]) - Peripheral neuropathy
*Myonal ([[eperisone]]) - Muscle relaxant
*Myonal ([[eperisone]]) - Muscle relaxant
*Selbex ([[teprenone]]) - Gastric ulcers and gastritis
*Selbex ([[teprenone]]) - Gastric ulcers and gastritis
*Zonegran ([[zonisamide]]) - Partial-onset seizures
*Zonegran ([[zonisamide]]) - Partial-onset seizures
*Leqembi ([[Lecanemab]]) - Alzheimer’s Disease
⚫
*Gliadel Wafer ([[carmustine]]) - Treatment for Brain Tumors
⚫
*Lenvima ([[lenvatinib]]) - Thyroid Cancer or Kidney Cancer

===Aricept===
===Aricept===
Aricept accounted for 40% of Eisai's revenue as of March 2010.<ref name=bb20110425>{{cite news |title=Eisai Aricept Patch for Alzheimer's Isn't Ready for Approval |author=Kanoko Matsuyama |agency=[[Bloomberg L.P.]] |date=April 25, 2011 |accessdate=April 25, 2011 |url=https://www.bloomberg.com/news/2011-04-25/eisai-says-fda-indicates-aricept-nda-not-ready-for-approval.html }}</ref> The main competitor to Aricept is a generic formulation from [[Ranbaxy Laboratories|Ranbaxy Labs]].<ref name=bb20110425/> Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.<ref name=bb20110425/>
Aricept accounted for 40% of Eisai's revenue as of March 2010.<ref name=bb20110425>{{cite news |title=Eisai Aricept Patch for Alzheimer's Isn't Ready for Approval |author=Kanoko Matsuyama |agency=[[Bloomberg L.P.]] |date=April 25, 2011 |access-date=April 25, 2011 |url=https://www.bloomberg.com/news/2011-04-25/eisai-says-fda-indicates-aricept-nda-not-ready-for-approval.html }}</ref> The main competitor to Aricept is a generic formulation from [[Ranbaxy Laboratories|Ranbaxy Labs]].<ref name=bb20110425/> Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.<ref name=bb20110425/>


==See also==
==See also==
Line 79: Line 93:


==References==
==References==
{{reflist}}
{{Reflist}}


==External links==
==External links==
* {{Official website}}
* {{Official website}}

* {{Webarchive|url=https://web.archive.org/web/20111206032138/http://us.eisai.com/award.asp?ID=169|date=December 6, 2011|title=Eisai awards and honors}}
* {{cite web |author=Michael Rosen |url=http://wtnnews.com/articles/2945/ |title=Big Pharma companies of 2005 |publisher=WTN News |date=May 9, 2006|accessdate=6 November 2015 }}
* {{cite web|url=http://www.nccjapan.net/shashiwiki/index.php?title=Ezai|title=Company history books (Shashi)|publisher=Shashi Interest Group|date=April 2016}} Wiki collection of bibliographic works on Eisai


{{TOPIX 100}}
{{TOPIX 100}}
{{Nikkei 225}}
{{Nikkei 225}}
{{Authority control}}


[[Category:Life sciences industry]]
[[Category:Life sciences industry]]
[[Category:Pharmaceutical companies based in Tokyo]]
[[Category:Pharmaceutical companies based in Tokyo]]
[[Category:Companies listed on the Tokyo Stock Exchange]]
[[Category:Companies listed on the Tokyo Stock Exchange]]
[[Category:Companies in the Nikkei 225]]
[[Category:Pharmaceutical companies established in 1941]]
[[Category:Pharmaceutical companies established in 1941]]
[[Category:Japanese companies established in 1941]]
[[Category:Japanese companies established in 1941]]
[[Category:Japanese brands]]
[[Category:Japanese brands]]
[[Category:Pharmaceutical companies based in New Jersey]]

Latest revision as of 10:01, 2 July 2024

Eisai Co., Ltd.
Native name
エーザイ株式会社
Ēzai kabushiki gaisha
Company typePublic KK
TYO: 4523
TOPIX Large 70 Component
TOPIX 100 Component
Nikkei 225 Component
IndustryPharmaceuticals
FoundedDecember 6, 1941; 82 years ago (1941-12-06)
FounderToyoji Naito
Headquarters4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
Key people
Haruo Naito
(President and CEO)
Products
RevenueIncrease ¥ 741.8 billion (2023)[1]
Increase ¥ 53.4 billion (2023)[1]
Increase ¥ 43.8 billion (2023)[1]
Total assetsIncrease ¥ 743.9 billion (2023)[1]
Total equityIncrease ¥ 430.2 billion (2023)[1]
OwnerThe Master Trust Bank of Japan (11.78%)
Japan Trustee Services Bank (10.99%)
Nippon Life (4.29%)[2]
Number of employees
Increase 10,000 (2023)[1]
WebsiteOfficial website
Footnotes / references
[2] [1]

Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.[3]

History[edit]

Nihon Eisai Co. Ltd. was established in 1941.[4] In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.[5] The American subsidiary of the company, Eisai Inc., was established in 1995.[6]

On November 25, 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer.[7]

Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson.

In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals.[8]

In April 2007, Eisai acquired Exton, Pennsylvania-based Morphotek, a company developing therapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases.

In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for US$3.9 billion.[9] This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio.

In 2009, Eisai received the Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Banzel (rufinamide).[10]

In June 2023, the company suffered from a ransomware attack, causing a shutdown of some of its logistical systems.[11]

Lecanemab, branded as "Leqembi" was approved by the U.S. Food and Drug Administration (FDA) in January 2023 under an Accelerated Approval pathway.[12] The approval was converted into a traditional approval in July 2023.[13]

Locations[edit]

Eisai Co., Ltd. is based in Tokyo, Japan, while its American subsidiary, Eisai Inc., is headquartered in Nutley, New Jersey. Eisai Inc. is led by Ivan Cheung as CEO.[14] Eisai maintains medical research headquarters in Nutley as well as at locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute and the Genetics Guided Dementia Discovery (G2D2) institute are based.[15][16]

The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.

Products[edit]

Some of the key products that Eisai produces or markets with partners include:

Aricept[edit]

Aricept accounted for 40% of Eisai's revenue as of March 2010.[17] The main competitor to Aricept is a generic formulation from Ranbaxy Labs.[17] Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.[17]

See also[edit]

References[edit]

  1. ^ a b c d e f g "Eisai Financial Summary 2023" (PDF). Retrieved July 2, 2024.
  2. ^ a b "Eisai Financial Summary 2019" (PDF). Retrieved December 21, 2020.
  3. ^ "Components:Nikkei Stock Average". Nihon Keizai Shimbun. Retrieved February 9, 2015.
  4. ^ "Eisai: The First 80 Years | Eisai Co., Ltd".
  5. ^ Winograd, Claudia (October 16, 2007). "Eisai (Japan)". In Colditz, Graham A. (ed.). Encyclopedia of Cancer and Society. SAGE Publications. doi:10.4135/9781412953979. ISBN 9781412949897. Archived from the original on February 9, 2015. Retrieved February 9, 2015.
  6. ^ "Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc" (Press release). Businesswire. Retrieved February 9, 2015.
  7. ^ "27 Nov 1996, Page 11 - The Cincinnati Enquirer at". Newspapers.com. November 27, 1996. Retrieved June 5, 2022.
  8. ^ "Eisai Inc. Buys 4 Cancer Drugs From Ligand Pharmaceuticals Inc. For $205 Million". BioSpace. Retrieved February 21, 2020.
  9. ^ "Japan's Eisai to buy MGI Pharma for $3.9 bln". Reuters. December 10, 2007. Retrieved November 20, 2019.
  10. ^ "NORD to Honor Rare Disease Pioneers". PR Newswire. May 11, 2009. Archived from the original on February 9, 2015. Retrieved February 9, 2015.
  11. ^ "Pharmaceutical Giant Eisai Takes Systems Offline Following Ransomware Attack". June 8, 2023.
  12. ^ Commissioner, Office of the (January 6, 2023). "FDA Grants Accelerated Approval for Alzheimer's Disease Treatment". FDA. Retrieved July 2, 2024.
  13. ^ Commissioner, Office of the (July 7, 2023). "FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval". FDA. Retrieved July 2, 2024.
  14. ^ Bell, Jacob (February 6, 2023). "Eisai gives first glimpse into Alzheimer's drug launch". BiopharmaDive. Washington, D.C.: Informa. Archived from the original on February 6, 2023. Retrieved February 11, 2023.
  15. ^ Carroll, John (September 15, 2016). "Eisai launches biotech division in Massachusetts aimed at Alzheimer's, I/O and autoimmune diseases". Endpoint News. Retrieved November 4, 2016.
  16. ^ "Eisai Launches Facility to Advance Precision Medicine". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). October 15, 2016. p. 8.
  17. ^ a b c Kanoko Matsuyama (April 25, 2011). "Eisai Aricept Patch for Alzheimer's Isn't Ready for Approval". Bloomberg L.P. Retrieved April 25, 2011.

External links[edit]


Retrieved from "https://en.wikipedia.org/w/index.php?title=Eisai_(company)&oldid=1232171902"